Iovance Biotherapeutics, Inc.(IOVA)

Description: Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The Company's lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.

---

Keywords: Medicine Cancer Biopharmaceutical Clinical Medicine Solid Tumors Oncology Immune System Immunotherapy Cancer Treatment Cell Therapy Cancer Immunotherapy Antineoplastic Drugs Melanoma Head And Neck Cancer Pembrolizumab Checkpoint Inhibitor Cancer Cell National Cancer Institute Metastatic Melanoma Lymphocytes Adoptive Cell Transfer Immunotherapy Products Treatment Of Metastatic Melanoma Cancer Immunotherapy Product Ocular Melanoma Breast And Lung Cancer Tumor Infiltrating Lymphocytes

---

Home Page: www.iovance.com

IOVA Technical Analysis

825 Industrial Road
San Carlos, CA 94070
United States
Phone: 650 260 7120

---

Officers

Exchange: NASDAQ

Country: US : United States of America

Currency: US Dollar ($)